RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum

Core Insights - RenovoRx has significantly increased its commercial presence, with 12 U.S. cancer centers now utilizing the RenovoCath device, and a total of 33 centers requesting access, tripling the potential commercial centers since Q1 2025 [1][2] - The company has successfully completed over 700 RenovoCath procedures since receiving FDA clearance in 2014, indicating strong clinical adoption and physician satisfaction [1][4] - The appointment of Ramtin Agah, MD, as Executive Chairman is expected to enhance the company's commercial strategy and market penetration efforts [5][6] Commercial Progress - The number of cancer centers using RenovoCath has increased to 12, with additional centers preparing to launch, indicating a robust sales pipeline [1][2] - The company has seen a rise in repeat purchase orders from existing customers, reflecting strong demand and physician satisfaction with the RenovoCath device [3] - RenovoRx's sales and marketing team, launched in late 2025, has contributed to the growing adoption of RenovoCath, supported by real-world clinical evidence of its effectiveness [4] Financial Outlook - The company anticipates revenue expansion in 2026 due to the increasing clinical demand for RenovoCath as it integrates into cancer treatment paradigms [2] - In Q1 2025, three patients initiated treatment via the TAMP therapy across four cancer centers, with expectations of at least 10 new patients in the current year [5] - Approximately $900,000 in revenues were generated from RenovoCath sales in the first nine months of 2025, with several customers initiating repeat orders [9] Strategic Developments - The expanded role of Dr. Agah as Executive Chairman is aimed at leveraging his medical expertise to drive broader market adoption of RenovoCath [5][6] - The company is actively exploring further revenue-generating activities, either independently or in partnership with a medical device commercial partner, to meet anticipated demand [9] - RenovoRx is also evaluating its novel drug-device combination product candidate, IAG, in an ongoing Phase III trial, which could further enhance its product offerings [10][11]